Compare Stocks

→ AI “wealth window” is closing soon! (From Paradigm Press) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AIM AIM ImmunoTech	$0.47 -2.1%	$0.43	$0.32 ▼ $0.75	$23.36M	-0.1	213,895 shs	178,742 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AIM AIM ImmunoTech	-1.60%	-23.77%	+10.79%	+11.43%	-13.15%

Biden’s $374B Giveaway Into This Sector (Ad)

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AIM AIM ImmunoTech	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AIM AIM ImmunoTech	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AIM AIM ImmunoTech	$200K	116.79	N/A	N/A	$0.20 per share	2.34

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AIM AIM ImmunoTech	-$28.96M	-$0.60	N/A	∞	N/A	-14,337.62%	-121.69%	-97.91%	5/13/2024 (Estimated)

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AIM AIM ImmunoTech	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AIM AIM ImmunoTech	N/A	1.68	1.68

Ownership

Institutional Ownership

Company	Institutional Ownership
AIM AIM ImmunoTech	12.02%

Insider Ownership

Company	Insider Ownership
AIM AIM ImmunoTech	0.02%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
AIM AIM ImmunoTech	22	49.90 million	49.89 million	Not Optionable

MNZS, AIM, OFX, MER, and RPS Headlines

Source	Headline
	AIM ImmunoTech Inc.: AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs finanznachrichten.de - April 15 at 9:00 PM
	AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs globenewswire.com - April 15 at 8:55 AM
	AIM ImmunoTech Announces Release of the Next CEO Corner Segment globenewswire.com - April 11 at 11:00 AM
	Advance Notice Bylaw Cross-Appeals Ask Supreme Court for Reframed Analysis law.com - April 10 at 8:58 PM
	Aim ImmunoTech Announces Positive Data From Ampligen Study In Combination With Pembrolizumab markets.businessinsider.com - April 10 at 10:49 AM
	AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer globenewswire.com - April 10 at 8:21 AM
	Nearly 600 cars recovered in sweeping auto theft crackdown in Ontario, Quebec: police ca.news.yahoo.com - April 5 at 1:45 AM
	Earnings call: AIM ImmunoTech optimistic on Ampligen's future in oncology investing.com - April 4 at 3:44 PM
	Challenges to Advance Notice Bylaws Are Spiking jdsupra.com - April 3 at 7:25 PM
	AIM ImmunoTech Inc. (AMEX:AIM) Q4 2023 Earnings Call Transcript insidermonkey.com - April 3 at 9:23 AM
	Q4 2023 AIM ImmunoTech Inc Earnings Call finance.yahoo.com - April 2 at 11:20 PM
	AIM Stock Earnings: AIM ImmunoTech Misses EPS, Beats Revenue for Q4 2023 markets.businessinsider.com - April 2 at 12:49 PM
	AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update globenewswire.com - April 2 at 7:30 AM
	AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference globenewswire.com - March 28 at 8:05 AM
	AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast globenewswire.com - March 26 at 9:05 AM
	AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research globenewswire.com - March 25 at 9:05 AM
	AIM ImmunoTech Inc. (NYSE:AIM) Director Purchases $15,000.18 in Stock insidertrades.com - March 23 at 9:28 AM
	AIM ImmunoTech Announces Release of the Next CEO Corner Segment globenewswire.com - March 22 at 8:55 AM
	AIM ImmunoTech Announces Release of the Next CEO Corner Segment globenewswire.com - March 20 at 9:25 AM
	AIM ImmunoTech Inc. (NYSE:AIM) COO Peter W. Rodino III Buys 37,879 Shares insidertrades.com - March 19 at 5:55 AM
	AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity globenewswire.com - March 15 at 8:45 AM
	AIM ImmunoTech launches CEO Corner for direct stakeholder engagement investing.com - March 9 at 3:55 PM
	Plaintiffs’ Firms Extracting Fees Based on Newly Invalidated Advance Notice Bylaw Provisions jdsupra.com - March 7 at 4:03 PM
	AIM ImmunoTech Announces Launch of CEO Corner Platform globenewswire.com - March 7 at 8:45 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Value Stocks Too Small For Buffett’s Portfolio
March 28, 2024 12:16 PM
View 3 Value Stocks Too Small For Buffett’s Portfolio
Canoo, Inc. Bites the Dust: Mullen Automotive Is a Better Bet
April 2, 2024 9:15 AM
View Canoo, Inc. Bites the Dust: Mullen Automotive Is a Better Bet
5 Cheap Dividend Stocks: Which to Buy Now
April 1, 2024 9:55 AM
View 5 Cheap Dividend Stocks: Which to Buy Now
3 High Dividend Stocks to Replace Lower Savings Yields Ahead
April 9, 2024 9:15 AM
View 3 High Dividend Stocks to Replace Lower Savings Yields Ahead
Bargain Alert: AMD is on the Verge of a Massive Catchup Play
April 4, 2024 8:56 AM
View Bargain Alert: AMD is on the Verge of a Massive Catchup Play

All Headlines

Company Descriptions

AIM ImmunoTech

NYSE:AIM

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; Pharmaceutics International Inc.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial